Related Experiment Videos
[Treatment of Wilson's disease in children. Five case reports]
Insights
This study reports on five children with Wilson's disease treated with D-penicillamine, showing encouraging liver improvements and potential reversal of portal hypertension. Long-term follow-up suggests this chelating agent is effective for managing this genetic liver condition.
Area of Science:
- Hepatology
- Pediatric Gastroenterology
- Clinical Therapeutics
Background:
- Wilson's disease is a rare genetic disorder characterized by excessive copper accumulation, primarily affecting the liver and nervous system.
- Pediatric Wilson's disease often presents with significant liver involvement, necessitating early and effective therapeutic interventions.
- Management of Wilson's disease requires addressing copper imbalance and its subsequent complications, such as liver damage and portal hypertension.
Observation:
- The study details five pediatric cases of Wilson's disease with predominant liver manifestations.
- Treatment involved D-penicillamine, a chelating agent used to correct copper imbalance.
- Follow-up data, exceeding three years in four cases, were analyzed to assess therapeutic outcomes.
Findings:
- D-penicillamine administration led to encouraging improvements in liver function, evidenced by clinical, biological, and histological assessments.
- A decrease in spleen size and resolution of hypersplenism suggest potential reversibility of portal hypertension.
- Cupruria levels were monitored but noted to require interpretation alongside other factors, indicating its limitations as a sole indicator.
Implications:
- D-penicillamine therapy appears effective in managing pediatric Wilson's disease, showing positive effects on liver health and portal hypertension.
- The findings support the use of D-penicillamine as a primary treatment modality, highlighting the need for careful monitoring of copper excretion.
- Management strategies for portal hypertension in Wilson's disease should prioritize non-surgical approaches, given the potential for reversibility with medical treatment.
Abstract:
Reporting 5 cases of Wilson' disease occuring in children and expressed by a major liver involvement, the practical aspects of therapy are discussed. In 4 cases, follow-up exceeded 3 years. 1. D-Penicillillamine, a chelating agent, is administered for the purpose of inverting the cupric balance. Cupruria has, therefore, no absolute value and must be interpreted according to multiple factors. 2. The effects of D-penicillamine on the liver, as assessed by clinical, biological and histological data, appears encouraging. Laparoscopic examinations, so as to appreciate the evolution of the cirrhosis are still lacking. 3. The decrease in spleen size and signs of hypersplenism probably illustrate the reversibility of the portal hypertension. In Wilson's disease, portal hypertension requires special measures which exclude surgical portal diversion.